William Blair analyst Ryan Daniels has reiterated their bullish stance on PRVA stock, giving a Buy rating on August 19.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ryan Daniels has given his Buy rating due to a combination of factors including Privia Health Group’s impressive performance in the Medicare Shared Savings Program (MSSP). The company achieved a significant increase in shared savings for the 2024 performance year, which led to an upward revision of their 2025 adjusted EBITDA guidance. This reflects strong operational execution and financial health.
Furthermore, Daniels views Privia Health as a key player in the healthcare sector poised for substantial growth. The company’s scalable business model and positive macroeconomic factors are expected to drive significant expansion in revenue and profitability. The stock is considered undervalued relative to its market leadership and growth potential, making it an attractive investment opportunity.
In another report released on August 19, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $24.00 price target.